Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus

Diabetes Metab Syndr Obes. 2024 Feb 8:17:647-659. doi: 10.2147/DMSO.S447784. eCollection 2024.


Purpose of review: The aim of this review is to summarize the role of gastrointestinal microbiome (GM) in the development of type 2 diabetes mellitus (T2DM). Besides, we discuss the feasibility of applying FMT in the treatment of T2DM and propose a series of processes to refine the use of FMT in the treatment of T2DM.

Recent findings: T2DM is a metabolic disease which is connected with the GM. According to many researches, GM can produce a variety of metabolites such as bile acid, short chain fatty acids, lipopolysaccharides and trimethylamine oxide which play an important role in metabolism. FMT is a method to regulate GM and has been observed to be effective in the treatment of metabolic diseases such as T2DM in some mouse models and people. However, there is still a lack of direct evidence for the use of FMT in the treatment of T2DM, and the process of FMT is not standardized.

Summary: Dysregulation of GM is closely related to the development of T2DM. Promoting the conversion of GM in T2DM patients to normal population through FMT can reduce insulin resistance and lower their blood glucose level, which is an optional treatment for T2DM patients in the future. At present, the feasibility and limitations of applying FMT to the treatment of T2DM need to be further studied.

Keywords: fecal microbiota transplantation; gastrointestinal microbiome; treatment; type 2 diabetes mellitus.

Publication types

  • Review

Grants and funding

This work is supported by Construction of an innovative system of traditional Chinese medicine wisdom management of metabolic diseases based on Internet of Things technology and its regional application (CKY2021088).